Isis Pharmaceuticals (IONS) Long-Term Debt to Capital Ratio

Ionis Pharmaceuticals - graphic logo of issuer IONS

This GURU.Markets price chart illustrates the price action of Ionis Pharmaceuticals (IONS), whose strategy is based on licensing rights to pharmaceutical companies for a fee, ensuring high returns. The current indicator is 4.95. Currently, R&D centers are developing revolutionary therapies to combat heart and brain pathologies. Risks are minimized through a broad development pipeline and strategic collaborations with market leaders.

Ionis Pharma (IONS): Long-Term Debt to Capital from 07/04/2022 to 10/30/2026

Analytical breakdowns for Ionis Pharmaceuticals

- current price and projected stock value:
Share Price Ionis Pharmaceuticals, Inc.|IONS - Price Target Chart
- market capitalization details:
Market Capitalization Ionis Pharmaceuticals|IONS - Enterprise Value
- issuer book value statistics:
Book Value per Share Ionis|IONS - Book Capitalization|Market Capitalization to Book Value ionispharma.com|IONS - Aggregate Company Assets
- debt and solvency information:
Debt to Capital Ionis Pharmaceuticals|IONS - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio ionispharma.com|IONS - Company Aggregate Debts|Debts to Net Assets Ionis Pharmaceuticals|IONS - Company Long-Term Debt|Short-Term Debt Volume Ionis|Intermediate Coverage Ratio ionispharma.com
- net income and valuation ratios data:
IONS - Company Net Income
Summary company analysis:Ionis Pharmaceuticals
Original product of Ionis Pharmaceuticals, Inc.

To assess the credit quality of Ionis Pharmaceuticals (IONS), the analyst utilizes the long-term financial leverage ratio, which compares liabilities with maturities exceeding one year against equity to determine the degree of reliance on borrowed funds. The stability of this metric is supported by an RNA drug diversification strategy and partnerships with pharma behemoths, which minimize the debt load and confirm the company's financial autonomy.

Analysis of competing companies

Long-Term Debt to Capital Ratio TEM (Tempus)|Long-Term Debt to Equity Qiagen Group (QGEN)|Repligen Inc. - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RNA (Avidity Biosciences)|Long-Term Debt to Capital crisprtx.com CRSP|GeneDx - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Ultragenyx Pharmaceutical Inc. RARE|Beam Therapeutics Corp (BEAM) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Sarepta Corp (SRPT)|Long-Term Debt to Equity Twist Bioscience|Long-Term Debt to Capital Ratio TXG (10xgenomics.com)|Long-Term Debt to Capital NTLA|Ratio of Long-Term Indebtedness to Capital Stoke Therapeutics Inc|Long-Term Debt to Equity BioLife Corp BLFS|Ratio of Long-Term Indebtedness to Capital Wave Pharma (WVE)|MAZE: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient SION (sionnatx.com)|Prime Medicine (PRME) - Long-Term Debt to Equity|Long-Term Liabilities to Equity TSHA (Taysha Gene Therapies Inc)|QURE (uniQure Corp) - Long-Term Debt to Capital|MGTX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital RGNX|Long-Term Debt to Capital solidbio.com (SLDB)|Long-Term Debt to Equity Ocugen OCGN|Long-Term Debt to Capital Coefficient PACB|BNTC - Long-Term Debt to Equity|Design Corp (DSGN) - Long-Term Debt to Equity Ratio|RCKT: Long-Term Debt to Capital|4dmoleculartherapeutics.com (FDMT) - Long-Term Debt to Capital|LXEO (Lexeo Therapeutics Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Korro Bio, Inc (KRRO)|Long-Term Debt to Capital EDIT|SLN - Long-Term Liabilities to Capital|ProQR Therapeutics - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Codexis Inc CDXS|SGMO: Long-Term Debt to Equity Ratio|Nautilus Biotechnology - Long-Term Loans to Capital Ratio|MGX: Long-Term Debt to Capital|DTIL - Ratio of Long-Term Indebtedness to Capital|GBIO (Generation Bio Co) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio boundlessbio.com (BOLD)|Long-Term Debt to Capital XCUR|Long-Term Debt to Capital imunon.com (IMNN)|Long-Term Debt to Equity Phio Pharmaceuticals Corp. PHIO|Mustang Bio Inc - Long-Term Debt to Equity|RNAZ - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Bionano Genomics, Inc. BNGO|APDN: Long-Term Debt to Capital|BLUE - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ImmunoPrecise Antibodies Ltd|Long-Term Liabilities to Capital Omega Therapeutics Corp OMGA|Long-Term Debt to Equity Singular Genomics Systems (OMIC)|regulusrx.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Equity Syros Pharmaceuticals, Inc. SYRS|Ratio of Long-Term Indebtedness to Capital Telesis Bio Inc. (TBIO)|TRACON - Long-Term Debt to Capital|UBX (Unity Biotechnology, Inc) - Long-Term Debt to Capital Ratio